A historic perspective on the current progress in elucidation of the biologic significance of non-neuronal acetylcholine.

Szczegóły
Abstrakt

Tytuł:: A historic perspective on the current progress in elucidation of the biologic significance of non-neuronal acetylcholine.
Autorzy:: Grando SA; Department of Dermatology, University of California, Irvine, CA 92697, USA.
Kawashima K; Department of Molecular Pharmacology, Kitasato University School of Pharmacy, Tokyo 108-8641, Japan.
Wessler I; Institute of Pathology, University Medical Center, Johannes Gutenberg-University, Mainz D-55101, Germany.
Źródło:: International immunopharmacology [Int Immunopharmacol] 2020 Apr; Vol. 81, pp. 106289. Date of Electronic Publication: 2020 Feb 26.
Typ publikacji:: Congress; Editorial
Język:: English
Imprint Name(s):: Original Publication: Amsterdam ; New York : Elsevier Science, c2001-
MeSH Terms:: Acetylcholine/*metabolism
Immune System Diseases/*metabolism
Neoplasms/*metabolism
Neurons/*physiology
Non-Neuronal Cholinergic System/*physiology
Animals ; Homeostasis ; Humans ; Interdisciplinary Communication ; Neuronal Plasticity
References:: Science. 2011 Oct 7;334(6052):98-101. (PMID: 21921156)
Genes Immun. 2011 Apr;12(3):222-30. (PMID: 21270829)
Proc Natl Acad Sci U S A. 1978 Jun;75(6):2902-4. (PMID: 275860)
J Physiol. 1933 Oct 6;79(3):255-85. (PMID: 16994462)
Front Immunol. 2019 May 31;10:1102. (PMID: 31214160)
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1572-6. (PMID: 1542648)
Clin Exp Pharmacol Physiol. 1999 Mar;26(3):198-205. (PMID: 10081614)
Nature. 2002 Dec 19-26;420(6917):853-9. (PMID: 12490958)
Nature. 2003 Jan 23;421(6921):384-8. (PMID: 12508119)
Life Sci. 2007 May 30;80(24-25):2314-9. (PMID: 17383684)
Biochem Biophys Res Commun. 2011 Nov 18;415(2):319-24. (PMID: 22027145)
Int Immunopharmacol. 2020 Mar;80:106149. (PMID: 31958740)
Dermatology. 2000;201(4):290-5. (PMID: 11146336)
Am J Physiol. 1980 Aug;239(2):G99-105. (PMID: 7406052)
Ukr Biokhim Zh (1999). 2011 Sep-Oct;83(5):13-21. (PMID: 22276424)
Proc Natl Acad Sci U S A. 1983 Oct;80(20):6413-7. (PMID: 6578516)
Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4703-7. (PMID: 1905013)
Int Immunopharmacol. 2015 Nov;29(1):87-92. (PMID: 25812766)
Protein Pept Lett. 2012 Feb;19(2):155-64. (PMID: 21933123)
Nat Rev Cancer. 2014 Jun;14(6):419-29. (PMID: 24827506)
Oncotarget. 2016 Sep 13;7(37):59199-59208. (PMID: 27409670)
J Neuroimmunol. 2007 Aug;188(1-2):80-5. (PMID: 17586055)
Cancer Res. 2003 Jan 1;63(1):214-21. (PMID: 12517800)
Life Sci. 2003 Feb 28;72(15):1745-56. (PMID: 12559395)
Front Pharmacol. 2019 Jan 07;9:1499. (PMID: 30687084)
J Biol Chem. 2019 Mar 22;294(12):4520-4528. (PMID: 30692201)
Handb Exp Pharmacol. 2012;(208):451-68. (PMID: 22222710)
J Pharmacol Sci. 2008 Feb;106(2):174-9. (PMID: 18285656)
Nat Rev Cancer. 2009 Mar;9(3):195-205. (PMID: 19194381)
Scand J Gastroenterol Suppl. 1980;66:5-11. (PMID: 6941378)
Sci Rep. 2017 Jan 19;7:40802. (PMID: 28102288)
Front Cell Neurosci. 2017 Sep 22;11:287. (PMID: 29018331)
Proc Natl Acad Sci U S A. 1990 May;87(9):3294-8. (PMID: 2159143)
Pharmacol Ther. 2000 Apr;86(1):29-48. (PMID: 10760545)
Prog Histochem Cytochem. 1975;7(3):1-52. (PMID: 1094493)
Curr Pharm Des. 2016;22(14):2170-7. (PMID: 26924207)
J Autoimmun. 2014 Jun;51:44-50. (PMID: 24397962)
J Am Acad Dermatol. 2017 May;76(5):895-902. (PMID: 28089115)
J Pharmacol Exp Ther. 1981 Aug;218(2):426-34. (PMID: 7252842)
Naunyn Schmiedebergs Arch Pharmacol. 1997 Apr;355(4):515-23. (PMID: 9109369)
Curr Pharm Des. 2016;22(14):2152-9. (PMID: 26818857)
FASEB J. 2006 Oct;20(12):2093-101. (PMID: 17012261)
J Physiol. 1929 Oct 23;68(2):97-123. (PMID: 16994063)
Arch Dermatol. 2004 Mar;140(3):327-34. (PMID: 15023776)
Front Biosci. 2004 Sep 01;9:2063-85. (PMID: 15353271)
J Comp Neurol. 2013 Nov;521(16):3741-67. (PMID: 23749724)
Ann N Y Acad Sci. 2012 Jul;1261:7-17. (PMID: 22823388)
Front Cell Neurosci. 2017 Jul 05;11:189. (PMID: 28725182)
Endocrinology. 2004 May;145(5):2498-506. (PMID: 14764638)
Front Immunol. 2018 Jul 30;9:1604. (PMID: 30105015)
Autoimmunity. 2012 Feb;45(1):36-43. (PMID: 21923617)
Front Immunol. 2017 Sep 06;8:1085. (PMID: 28932225)
Chem Biol Interact. 2013 Mar 25;203(1):269-76. (PMID: 23047026)
Biomolecules. 2019 Dec 04;9(12):. (PMID: 31817275)
Neurosci Lett. 1999 Apr 30;266(1):17-20. (PMID: 10336173)
Cancers (Basel). 2019 Mar 05;11(3):. (PMID: 30841571)
Cancer Cells. 1991 Dec;3(12):511-6. (PMID: 1820094)
J Invest Dermatol. 2002 Oct;119(4):943-8. (PMID: 12406342)
Scand J Gastroenterol. 2011 Apr;46(4):446-55. (PMID: 21265716)
Neurosci Lett. 1977 Sep;5(6):345-9. (PMID: 19605018)
PLoS One. 2013;8(3):e57587. (PMID: 23505434)
Eur J Pharmacol. 2009 May 1;609(1-3):27-33. (PMID: 19285065)
J Invest Dermatol. 2006 Aug;126(8):1879-84. (PMID: 16763548)
Clin Rev Allergy Immunol. 2012 Jun;42(3):298-308. (PMID: 21207192)
J Physiol. 1980 Feb;299:521-31. (PMID: 6247483)
Proc R Soc Med. 1935 Jan;28(3):319-32. (PMID: 19990108)
J Natl Cancer Inst. 1978 Sep;61(3):923-6. (PMID: 29133)
Physiol Genomics. 2006 Nov 27;27(3):391-7. (PMID: 16940431)
Br J Pharmacol. 2008 Aug;154(8):1558-71. (PMID: 18500366)
Sci Transl Med. 2014 Aug 20;6(250):250ra115. (PMID: 25143365)
Eur J Pharmacol. 1969 Aug;7(2):143-51. (PMID: 4390564)
Biochem J. 1914 Feb;8(1):44-9. (PMID: 16742288)
Lancet. 1977 Jun 18;1(8025):1310-1. (PMID: 68406)
J Investig Dermatol Symp Proc. 1997 Aug;2(1):41-8. (PMID: 9487015)
FEBS Lett. 1979 Sep 15;105(2):296-8. (PMID: 226413)
Grant Information:: R13 TR001693 United States TR NCATS NIH HHS
Substance Nomenclature:: N9YNS0M02X (Acetylcholine)
Entry Date(s):: Date Created: 20200301 Date Completed: 20210106 Latest Revision: 20231030
Update Code:: 20240105
PubMed Central ID:: PMC10612399
DOI:: 10.1016/j.intimp.2020.106289
PMID:: 32113128
: Opinia redakcyjna

Full Text Finder

The "5 th International Symposium on Non-neuronal Acetylcholine: from bench to bedside" was held on September 27-29, 2019 in Hyatt Regency, Long Beach, CA, USA. Approximately 50 scientists from 11 countries over 6 continents participated in this meeting. The major topics included an overall biologic significance of non-neuronal acetylcholine (ACh) and the roles of the non-neuronal cholinergic systems in mucocutaneous, respiratory, digestive, immunologic, endocrine, cardiovascular, musculoskeletal and kidney diseases, and cancer. This meeting facilitated continued work to advance the fundamental science and translational aspects of the interdisciplinary studies on non-neuronal ACh. The progress made has opened a new chapter in the field of cholinergic pharmacology, and advanced our knowledge beyond regulation of individual cell- and tissue-types, defining a new paradigm of selective pharmacological regulation of vital function of practically all types of non-neuronal cells. It is now clear that the autocrine and paracrine control of non-neuronal cells by non-neuronal ACh is implemented through synergistic, additive, and reciprocal effects triggered by two different cholinergic receptor classes. Each biologic effect of ACh is determined by a unique combination of cholinergic receptors subtype expressed at each stage of cell development and differentiation. The plasticity of the non-neuronal cholinergic system helps adjust homeostasis to new environmental conditions.
Competing Interests: Declaration of Competing Interest The authors have no competing interests to declare
(Copyright © 2020 Elsevier B.V. All rights reserved.)

Informacja